BRPI0915834A2 - 6-(1-piperazinil)-piridazinas substituídas como antagonistas do receptor de 5-ht6 - Google Patents
6-(1-piperazinil)-piridazinas substituídas como antagonistas do receptor de 5-ht6Info
- Publication number
- BRPI0915834A2 BRPI0915834A2 BRPI0915834A BRPI0915834A BRPI0915834A2 BR PI0915834 A2 BRPI0915834 A2 BR PI0915834A2 BR PI0915834 A BRPI0915834 A BR PI0915834A BR PI0915834 A BRPI0915834 A BR PI0915834A BR PI0915834 A2 BRPI0915834 A2 BR PI0915834A2
- Authority
- BR
- Brazil
- Prior art keywords
- pyridazines
- piperazinyl
- substituted
- receptor antagonists
- antagonists
- Prior art date
Links
- MIPXOMNITKFHDA-UHFFFAOYSA-N 3-piperazin-1-ylpyridazine Chemical class C1CNCCN1C1=CC=CN=N1 MIPXOMNITKFHDA-UHFFFAOYSA-N 0.000 title 1
- 108091005435 5-HT6 receptors Proteins 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/22—Nitrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08159591 | 2008-07-03 | ||
| PCT/EP2009/004745 WO2010000456A1 (en) | 2008-07-03 | 2009-07-01 | Substituted 6- (1-piperazinyl) -pyridazines as 5-ht6 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0915834A2 true BRPI0915834A2 (pt) | 2015-11-03 |
Family
ID=39776599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0915834A BRPI0915834A2 (pt) | 2008-07-03 | 2009-07-01 | 6-(1-piperazinil)-piridazinas substituídas como antagonistas do receptor de 5-ht6 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8530474B2 (pt) |
| EP (1) | EP2310374B1 (pt) |
| JP (1) | JP5417439B2 (pt) |
| CN (1) | CN102159554B (pt) |
| AR (1) | AR072547A1 (pt) |
| AU (1) | AU2009266001B2 (pt) |
| BR (1) | BRPI0915834A2 (pt) |
| CA (1) | CA2729313C (pt) |
| ES (1) | ES2398625T3 (pt) |
| MX (1) | MX2011000043A (pt) |
| RU (1) | RU2502734C2 (pt) |
| TW (1) | TWI436995B (pt) |
| WO (1) | WO2010000456A1 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2769B1 (en) | 2005-10-26 | 2014-03-15 | جانسين فارماسوتيكا ان. في | Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor |
| JO2849B1 (en) * | 2007-02-13 | 2015-03-15 | جانسين فارماسوتيكا ان. في | Dopamine 2 receptor antagonists are rapidly hydrolyzed |
| EP2137162B1 (en) * | 2007-03-15 | 2018-08-01 | Novartis AG | Organic compounds and their uses |
| WO2008128996A1 (en) * | 2007-04-23 | 2008-10-30 | Janssen Pharmaceutica N.V. | Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists |
| KR20100016498A (ko) * | 2007-04-23 | 2010-02-12 | 얀센 파마슈티카 엔.브이. | 속해리성 도파민 2 수용체 길항제로서의 피리딘 유도체 |
| JP5431305B2 (ja) * | 2007-04-23 | 2014-03-05 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 高速解離性ドパミン２受容体アンタゴニストとしての４−アルコキシピリダジン誘導体 |
| US20100041663A1 (en) | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
| EP2307374B1 (en) * | 2008-07-31 | 2017-01-25 | Janssen Pharmaceutica NV | Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2341965C3 (de) | 1973-08-20 | 1979-01-25 | C.H. Boehringer Sohn, 6507 Ingelheim | 4- [N- (o-PyridyD- N-acyl] -aminolphenäthylpiperidine, Verfahren zu deren Herstellung sowie deren Verwendung bei der Bekämpfung von Schmerzzuständen |
| US4197304A (en) | 1975-09-23 | 1980-04-08 | Janssen Pharmaceutica N.V. | N-Aryl-N-(1-L-4-piperidinyl)-arylacetamides |
| NO147672C (no) | 1975-09-23 | 1983-05-25 | Janssen Pharmaceutica Nv | Analogifremgangsmaate for fremstilling av n-aryl-n-(1-l1-4-piperidinyl)-arylacetamider |
| EG12406A (en) | 1976-08-12 | 1979-03-31 | Janssen Pharmaceutica Nv | Process for preparing of novel n-aryl-n-(1-l-4-piperidinyl)-arylacetamides |
| DE3218482A1 (de) | 1982-05-15 | 1983-11-17 | Bayer Ag, 5090 Leverkusen | Substituierte 5-trifluormethyl-1,3,4-thiadiazol-2-yloxyessigsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als herbizide |
| MX173362B (es) | 1987-03-02 | 1994-02-23 | Pfizer | Compuestos de piperazinil heterociclicos y procedimiento para su preparacion |
| GB9216298D0 (en) | 1991-08-15 | 1992-09-16 | Ici Plc | Piperidine derivatives |
| TW406075B (en) | 1994-12-13 | 2000-09-21 | Upjohn Co | Alkyl substituted piperidinyl and piperazinyl anti-AIDS compounds |
| US5753679A (en) | 1995-05-10 | 1998-05-19 | Hoffmann-La Roche Inc. | Benzyl-piperidine derivatives |
| MY116093A (en) | 1996-02-26 | 2003-11-28 | Upjohn Co | Azolyl piperazinyl phenyl oxazolidinone antimicrobials |
| AU8457298A (en) | 1997-08-15 | 1999-03-08 | Pfizer Products Inc. | 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1H-indole derivatives interacting with the dopamine D4 receptor |
| KR100261139B1 (ko) | 1998-01-16 | 2000-08-01 | 황준수 | 신규한 알릴티오피리다진 유도체 및 그의 제조방법 |
| AR028948A1 (es) | 2000-06-20 | 2003-05-28 | Astrazeneca Ab | Compuestos novedosos |
| WO2002068409A1 (en) | 2001-02-23 | 2002-09-06 | Merck & Co., Inc. | N-substituted nonaryl-heterocyclic nmda/nr2b antagonists |
| EP1443046B1 (en) | 2001-10-09 | 2008-12-17 | Kyorin Pharmaceutical Co., Ltd. | Novel 4-(2furoyl)aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same |
| AU2002360561A1 (en) | 2001-12-11 | 2003-06-23 | Sepracor, Inc. | 4-substituted piperidines, and methods of use thereof |
| CA2474322A1 (en) | 2002-01-25 | 2003-07-31 | Kylix Pharmaceuticals B.V. | 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2 |
| AU2003203148A1 (en) | 2002-02-05 | 2003-09-02 | High Point Pharmaceuticals, Llc | Novel aryl- and heteroarylpiperazines |
| EP1478361A2 (en) * | 2002-02-22 | 2004-11-24 | PHARMACIA & UPJOHN COMPANY | Arylsulfone derivatives |
| JP4467307B2 (ja) * | 2002-02-22 | 2010-05-26 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | ５−ｈｔ受容体アンタゴニストとしてのピリジルスルホン誘導体 |
| SE0201544D0 (sv) | 2002-05-17 | 2002-05-17 | Biovitrum Ab | Novel compounds and thier use |
| JP3625214B2 (ja) | 2002-09-26 | 2005-03-02 | 株式会社マンダム | 防腐殺菌剤並びに該防腐殺菌剤を配合した化粧料、医薬品及び食品 |
| BRPI0410239A (pt) | 2003-05-08 | 2006-05-16 | Kyorin Seiyaku Kk | composto de 4-(2-furoil)aminopiperidina e medicamento |
| WO2005005779A2 (en) | 2003-07-14 | 2005-01-20 | Genesis Mining Technologies (Pty) Ltd | Dual retention cutting arrangement |
| CA2532236C (en) | 2003-07-29 | 2011-08-23 | Novo Nordisk A/S | Pyridazinyl- piperazines and their use as histamine h3 receptor ligands |
| RU2326118C2 (ru) * | 2003-07-30 | 2008-06-10 | Зинон Фармасьютиклз Инк. | Производные пиридазина и их применение в качестве терапевтических агентов |
| JP2007501801A (ja) | 2003-08-07 | 2007-02-01 | 日本たばこ産業株式会社 | ピロロ［１，２−ｂ］ピリダジン誘導体 |
| CA2563963A1 (en) | 2004-04-28 | 2005-11-10 | Pfizer Inc. | 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor |
| CA2568524A1 (en) | 2004-05-28 | 2005-12-15 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| JP4958786B2 (ja) | 2004-09-20 | 2012-06-20 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 複素環誘導体および治療薬としてのそれらの使用 |
| CA2585172C (en) | 2004-10-29 | 2014-08-12 | Kalypsys, Inc. | Sulfonyl-substituted bicyclic compounds as modulators of ppar |
| JP2008546784A (ja) | 2005-06-20 | 2008-12-25 | シェーリング コーポレイション | ヒスタミンｈ３アンタゴニストとして有用なピペリジン誘導体 |
| JO2769B1 (en) | 2005-10-26 | 2014-03-15 | جانسين فارماسوتيكا ان. في | Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor |
| WO2007130383A2 (en) | 2006-04-28 | 2007-11-15 | Northwestern University | Compositions and treatments using pyridazine compounds and secretases |
| KR101117931B1 (ko) | 2006-08-15 | 2012-04-12 | 에프. 호프만-라 로슈 아게 | 페닐, 피리딘 및 퀴놀린 유도체 |
| CA2606658A1 (en) | 2006-10-13 | 2008-04-13 | Mike Tyers | Compositions and methods for treating neurological disorders or damage |
| JO2642B1 (en) | 2006-12-08 | 2012-06-17 | جانسين فارماسوتيكا ان. في | Dopamine 2 receptor antagonists are rapidly hydrolyzed |
| JO2849B1 (en) * | 2007-02-13 | 2015-03-15 | جانسين فارماسوتيكا ان. في | Dopamine 2 receptor antagonists are rapidly hydrolyzed |
| JP5431305B2 (ja) | 2007-04-23 | 2014-03-05 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 高速解離性ドパミン２受容体アンタゴニストとしての４−アルコキシピリダジン誘導体 |
| KR20100016498A (ko) | 2007-04-23 | 2010-02-12 | 얀센 파마슈티카 엔.브이. | 속해리성 도파민 2 수용체 길항제로서의 피리딘 유도체 |
| WO2008128996A1 (en) | 2007-04-23 | 2008-10-30 | Janssen Pharmaceutica N.V. | Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists |
| AR068480A1 (es) | 2007-09-20 | 2009-11-18 | Glaxo Group Ltd | Compuesto de 4-heteroaril-piperidinil-n-substituido su uso para la preparacion de un medicamento util para el tratamiento de una afeccion en el que seria beneficioso el agonismo de un receptor muscarinico m1 y composicion farmaceutica que lo comprende |
| EP2307374B1 (en) | 2008-07-31 | 2017-01-25 | Janssen Pharmaceutica NV | Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists |
-
2009
- 2009-07-01 EP EP09772156A patent/EP2310374B1/en active Active
- 2009-07-01 BR BRPI0915834A patent/BRPI0915834A2/pt not_active IP Right Cessation
- 2009-07-01 CA CA2729313A patent/CA2729313C/en active Active
- 2009-07-01 US US13/002,413 patent/US8530474B2/en not_active Expired - Fee Related
- 2009-07-01 JP JP2011515236A patent/JP5417439B2/ja not_active Expired - Fee Related
- 2009-07-01 MX MX2011000043A patent/MX2011000043A/es active IP Right Grant
- 2009-07-01 RU RU2011103759/04A patent/RU2502734C2/ru active
- 2009-07-01 ES ES09772156T patent/ES2398625T3/es active Active
- 2009-07-01 WO PCT/EP2009/004745 patent/WO2010000456A1/en not_active Ceased
- 2009-07-01 AU AU2009266001A patent/AU2009266001B2/en not_active Ceased
- 2009-07-01 CN CN200980134982.0A patent/CN102159554B/zh not_active Expired - Fee Related
- 2009-07-02 TW TW098122349A patent/TWI436995B/zh not_active IP Right Cessation
- 2009-07-02 AR ARP090102473A patent/AR072547A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011526269A (ja) | 2011-10-06 |
| EP2310374B1 (en) | 2012-10-31 |
| US20110112107A1 (en) | 2011-05-12 |
| RU2502734C2 (ru) | 2013-12-27 |
| JP5417439B2 (ja) | 2014-02-12 |
| HK1158640A1 (en) | 2012-07-20 |
| CN102159554A (zh) | 2011-08-17 |
| AU2009266001A1 (en) | 2010-01-07 |
| ES2398625T3 (es) | 2013-03-20 |
| RU2011103759A (ru) | 2012-08-10 |
| EP2310374A1 (en) | 2011-04-20 |
| TWI436995B (zh) | 2014-05-11 |
| AU2009266001B2 (en) | 2014-03-27 |
| US8530474B2 (en) | 2013-09-10 |
| AR072547A1 (es) | 2010-09-08 |
| CN102159554B (zh) | 2014-09-24 |
| CA2729313C (en) | 2016-08-30 |
| TW201016684A (en) | 2010-05-01 |
| MX2011000043A (es) | 2011-02-22 |
| CA2729313A1 (en) | 2010-01-07 |
| WO2010000456A1 (en) | 2010-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2200033I1 (hu) | CGRP receptor antagonisták | |
| BRPI0919844A2 (pt) | compostos de azaindazol como antagonistas do receptor ccr1 | |
| BRPI0810462A2 (pt) | Derivados de quinolina-carboxamida como antagonistas de p2y12 | |
| BRPI0821141A2 (pt) | Derivados de heteroarila como antagonistas do receptor de orexina | |
| BRPI0909157A2 (pt) | compostos heterocíclicos como antagonistas de receptores de adenosina | |
| BRPI0817245A2 (pt) | Derivados e quinolina como antagonistas receptores de 5ht5a | |
| BRPI0717023A2 (pt) | Tiazol pirazolopirimidina como antagonistas do receptor de crf1 | |
| IL225978A0 (en) | Piperidinone carboxamide azaindane cgrp receptor antagonists | |
| PT2513093E (pt) | Novos antagonistas do receptor ccr2 e suas utilizações | |
| BRPI0910118A2 (pt) | antagonistas de receptores do glucagon | |
| BRPI1013821A2 (pt) | piridinas substituídas como antagonistas de ccr3. | |
| BRPI0717937A2 (pt) | Compostos de pirazona como antagonistas do receptor mineralocorticóide | |
| BRPI0913930A2 (pt) | antagonistas de receptores de prostaglandinas d2 | |
| DOP2007000068A (es) | Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2 | |
| BRPI0817061A2 (pt) | Derivados de pirrolidinilalquilisoquinolinona e -isoindolinona como antagonistas de histamina-3 | |
| BRPI0814806A2 (pt) | Pirazinas substituídas como antagonistas de cb1 | |
| BRPI0906838A2 (pt) | Pirimidinas como inibidores de quinase | |
| BRPI0815658A2 (pt) | Aril-éter pirrolidina como antagonistas do receptor nk3 | |
| BRPI1009398A2 (pt) | compostos de pirimidina fundida substituída | |
| BRPI0815674A2 (pt) | Aril-éter de pirrolidina como antagonista de receptor de nk3 | |
| BRPI0720078A2 (pt) | 2-aminoquinolinas como antagonistas de receptores de 5-ht(5a) | |
| BRPI0814767A2 (pt) | Derivados de monoamida como antagonistas do receptor de orexina | |
| CU23857B1 (es) | Nuevos derivados de benzamida como antagonistas de la bradiquinina | |
| EP2254413A4 (en) | IMIDAZOBENZAZEPIN-CGRP receptor antagonists | |
| SI3483163T1 (sl) | derivati triazolo(4,5-d)pirimidina kot antagonisti receptorja cb2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 10A ANUIDADE. |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2521 DE 30-04-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |